Qiagen NV (QGEN)
-NasdaqGS 19.46 
0.35(1.83%) Jun 17, 4:00PM EDT|After Hours
:
19.45 0.01 (0.05%) Jun 17, 4:38PM EDT
| Prev Close: | 19.11 |
|---|
| Open: | 19.38 |
|---|
| Bid: | 18.00 x 100 |
|---|
| Ask: | 22.00 x 300 |
|---|
| 1y Target Est: | 20.44 |
|---|
| Beta: | 0.86 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 19.26 - 19.55 |
|---|
| 52wk Range: | 15.90 - 22.20 |
|---|
| Volume: | 529,142 |
|---|
| Avg Vol (3m): | 716,505 |
|---|
| Market Cap: | 4.55B |
|---|
| P/E (ttm): | 38.92 |
|---|
| EPS (ttm): | 0.50 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Supreme Court's Ruling On Genetic Tests Will Make A Bad Business Worseat Forbes(Fri, Jun 14)
- 3 Stocks Boosting The Diversified Services Industry Higherat TheStreet(Wed, Jun 12)
- Qiagen Attempts to Expand NGS PlatformZacks(Tue, Jun 11)
- [$$] Quest/Hologic Pact Squeezes Qiagenat Barrons.com(Mon, Jun 10)
- Ingenuity Announces Significant Global Uptake of Variant Analysis Solution for Next-Generation SequencingBusiness Wire(Sun, Jun 9)
- QIAGEN Significantly Expands its Offering of Assay Panels for Next-generation Sequencing (NGS) Complemented by Ingenuity Analysis and Interpretation CapabilitiesPR Newswire(Fri, Jun 7)
- QIAGEN affirms FY13 view after Quest Diagnostics, Hologic strike dealat theflyonthewall.com(Thu, Jun 6)
- QIAGEN Comments on Decision by a U.S. Reference Laboratory Customer to Consolidate Purchase of Women's Health Tests with Competitor SupplierPR Newswire(Thu, Jun 6)
- Judgment Day for Myriad Geneticsat Motley Fool(Wed, Jun 5)
- How Vinegar Could Save 73,000 Women A Year From Cancerat Forbes(Sun, Jun 2)
- China Biotech In Review: Valeant Pharma Gains Sales Foothold In China With Bausch & Lomb Buyat Seeking Alpha(Sun, Jun 2)
- The Next Generation for Qiagen's Next-Gen Sequencing?at Motley Fool(Fri, May 31)
- QIAGEN Expands Pipeline of Promising New Biomarkers for Development of Personalized Healthcare Companion DiagnosticsPR Newswire(Fri, May 31)
- Qiagen N.V. Breaks Above 200-Day Moving Average - Bullish For QGENat TheStreet(Tue, May 28)
- Diabetes And Oncology Might Cushion Eli Lilly's Fall Off A Patent Cliffat Seeking Alpha(Fri, May 24)
Key Statistics
| Forward P/E (1 yr): | 16.78 |
|---|
| P/S (ttm): | 3.54 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 1.06 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.23 |
|---|
| Mean Recommendation*: | 2.9 |
|---|
| PEG Ratio (5 yr expected): | 2.05 |
|---|
Business Summary
QIAGEN N.V., through its subsidiaries, provides sample and assay technologies worldwide. It offers approximately 500 core consumable products, such as sample and assay kits, and automated instrumentation systems that empower customers to transform...
View More